Corrigendum to “Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review” [Biomed. Pharmacother. 92 (2017) 681–689]

Anjum, Komal; Shagufta, Bibi Ibtesam; Abbas, Syed Qamar; Patel, Seema; Khan, Ibrar Muhammad; Shah, Sayed Asmat Ali; Akhter, Najeeb; Shams-ul-Hassan, Syed

doi:10.1016/j.biopha.2018.02.102

Cited by 10 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A novel approach for treating GBM is therefore urgently needed, one that would address both pharmacodynamic as well as pharmacokinetic hurdles (3,4). Promising delivery strategies to overcome these problems in the clinics include convection enhanced delivery (CED) (5,6) and intrathecal injection (7,8).…”

Section: Introductionmentioning

confidence: 99%

Targeted brain tumor radiotherapy using an Auger emitter

Pirovano

Jannetti

Carter

et al. 2019

Preprint

View full text Add to dashboard Cite

One Sentence Summary:A novel PARP1-targeted Auger radiotherapeutic shows translational potential as a theranostic tool for imaging and killing cancer cells, resulting in tumor delineation and prolonged survival in a glioblastoma model. AbstractGlioblastoma multiforme is a highly aggressive form of brain cancer whose location, tendency to infiltrate healthy surrounding tissue, and heterogeneity significantly limit survival, with scant progress having been made in recent decades. 123 I-MAPi (Iodine-123 Meitner-Auger PARP1 inhibitor) is a precise therapeutic tool composed of a PARP1 inhibitor radiolabeled with an Auger-and gamma-emitting iodine isotope. Here, the PARP inhibitor, which binds to the DNA repair enzyme PARP1, specifically targets cancer cells, sparing healthy tissue, and carries a radioactive payload within reach of the cancer cells' DNA. The high relative biological efficacy of Auger electrons within their short range of action is leveraged to inflict DNA damage and cell death with high precision. The gamma ray emission of 123 I-MAPi allows for the imaging of tumor progression and therapy response, and for patient dosimetry calculation. Here we demonstrated the efficacy and specificity of this small molecule radiotheranostic in a complex preclinical model. In vitro and in vivo studies demonstrate high tumor uptake and a prolonged survival in mice treated with 123 I-MAPi when compared to vehicle controls. Different methods of drug delivery were investigated to develop this technology for clinical applications, including convection enhanced delivery (CED) and intrathecal injection. Taken together, these results represent the first full characterization of an Auger-emitting PARP inhibitor, demonstrate a survival benefit in mouse models of GBM, and confirm the high potential of 123 I-MAPi for clinical translation.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeted brain tumor radiotherapy using an Auger emitter

Pirovano

Jannetti

Carter

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Among various malignant tumors, gliomas are the most aggressive and wildly uncontrolled. 68,69 There still remains a huge challenge for precise theranostics of gliomas mainly due to the strongly infiltrative feature, the existence of blood-brain barrier (BBB), and the relatively deep sites of niduses inside the brain. 70 For this, Liu et al developed NIR-II absorptive OSNs for targeted PAI and imagingguided PTT toward brain tumor through scalp and skull ( Figure 6B).…”

Section: Photothermal Therapymentioning

confidence: 99%

Organic semiconducting nanomaterials‐assisted phototheranostics in near‐infrared‐II biological window

Yin

Lü

Fan

et al. 2020

VIEW

View full text Add to dashboard Cite

Phototheranostics conducted in the near-infrared-II (NIR-II) biological window exhibits high superiorities relative to that conducted in the first near-infrared (NIR-I) window due to higher penetration depth, higher signal-to-noise ratio of imaging, and improved maximum permissible exposure. Currently, most existing agents developed for NIR-II phototheranostics are limited to inorganic nanoparticles and small-molecule dyes, which suffer from the issues of longterm biotoxicity and poor photostability, respectively. Organic semiconducting nanomaterials (OSNs) constructed from π-conjugated organic semiconducting polymers or oligomers have unique advantages including high photostability, flexible optical features, and good biocompatibility due to the totally organic and biologically inert constituents. These advantages make OSNs more promising for in vivo phototheranostics. We here make a brief review about recent progress of OSNs-assisted phototheranostics conducted in the NIR-II biological window. NIR-II fluorescence imaging and photoacoustic imaging are mainly reviewed as diagnostic modalities to guide various treatments. Besides, multimodal phototheranostics using OSNs in NIR-II window is also described. At last, the challenges and outlook for OSNs-assisted NIR-II phototheranostics are discussed. K E Y W O R D S cancer therapy, fluorescence imaging, organic semiconducting nanoparticle, photoacoustic imaging, second near-infrared window This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

“…Glioma is a highly malignant tumor, especially glioblastoma (GBM). Despite continuous improvement in comprehensive treatment methods such as surgery, radiotherapy, chemotherapy and TTF, the survival time of patients with GBM has only increased from 12.1 to 14.6 months 1 . Thus, finding novel biomarkers is crucial to providing patients with gliomas with valid and reliable survival predictions as well as more aggressive treatment.…”

Section: Introductionmentioning

confidence: 99%

FAM72A promotes glioma progression by regulating mitophagy through the Pink1/Parkin signaling pathway

Zeng¹,

Xiong²,

Tang³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

Background: There is growing evidence that aberrant expression of FAM72A contributes to biological dysfunction, especially mitochondrial dysfunction. However, its role in most tumors remains unclear, especially in glioma. Methods: Herein, a high-throughput sequencing approach was used here to identify FAM72A as the target molecule. Next, we detected the protein and mRNA expression levels of FAM72A in normal brain tissue (NBT) as well as different grades of glioma tissue. CCK-8, colony formation, Transwell assays, and Western blotting, were all used to determine the molecular effects of FAM72A on glioma cells. Results: FAM72A was significantly upregulated in glioma, was significantly correlated with WHO grade and was associated with poor clinical outcomes. In functional assays, FAM72A was shown to promote glioma cell growth. Subsequent mechanistic studies indicated that FAM72A promoted glioma progression by regulating mitophagy through the Pink1/Parkin signaling pathway. In addition, FAM72A promoted mitophagy and maintained Pink1 stability through the Pink1/Parkin signaling pathway. Finally, FAM72A promoted tumor immune escape by upregulating PD-L1 expression. Conclusion: All of these data indicate that FAM72A confers an aggressive phenotype and poor prognosis on gliomas. Targeting FAM72A might represent a new therapeutic strategy for glioma.

show abstract

Corrigendum to “Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review” [Biomed. Pharmacother. 92 (2017) 681–689]

Cited by 10 publications

References 0 publications

Targeted brain tumor radiotherapy using an Auger emitter

Targeted brain tumor radiotherapy using an Auger emitter

Organic semiconducting nanomaterials‐assisted phototheranostics in near‐infrared‐II biological window

FAM72A promotes glioma progression by regulating mitophagy through the Pink1/Parkin signaling pathway

Contact Info

Product

Resources

About